01 noviembre 2012

JACC. The Effect of Age on Outcomes of Coronary Artery Bypass Surgery Compared With Balloon Angioplasty or Bare-Metal Stent Implantation Among Patients With Multivessel Coronary Disease.

Marcus Flather, MBBS; June-Wha Rhee, MD; Derek B. Boothroyd, PhD; Eric Boersma, PhD; Maria Mori Brooks, PhD; Didier Carrié, MD, PhD; Tim C. Clayton, MS; Nicholas Danchin, MD; Christian W. Hamm, MD; Whady A. Hueb, MD; Spencer B. King, MD; Stuart J. Pocock, PhD; Alfredo E. Rodriguez, MD, PhD; Patrick Serruys, MD; Ulrich Sigwart, MD; Rodney H. Stables, MD; Mark A. Hlatky, MD

A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials. Objectives: This study sought to assess whether patient age modifies the comparative effectiveness of coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI). J Am Coll Cardiol. 2012;60(21):2150-2157. doi:10.1016/j.jacc.2012.08.982. Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Contemporary Clinical Applications of Coronary Intravascular Ultrasound

Michael C. McDaniel, MD; Parham Eshtehardi, MD; Fadi J. Sawaya, MD; John S. Douglas, Jr, MD; Habib Samady, MD

Intravascular ultrasound (IVUS) provides valuable information on the coronary vascular lumen and wall and has been an important tool in the cardiac catheterization laboratory for over 2 decades. The major utility of IVUS relates to optimizing stent deployment, particularly in complex lesions. In percutaneous coronary intervention with bare-metal stents, IVUS guidance reduces restenosis. In percutaneous coronary intervention with drug-eluting stents, IVUS guidance may reduce rates of stent thrombosis with little affect on restenosis. The benefit of IVUS guidance is most important in complex lesion subsets, such as left main and bifurcation lesions, where studies suggest that IVUS guidance may reduce mortality. Whereas IVUS luminal area measurements have been used to assess intermediate lesion severity, recent studies have demonstrated that IVUS accurately identifies nonischemic lesions for which percutaneous coronary intervention can be safely deferred, but cannot accurately predict hemodynamically significant lesions and should not solely be used to justify revascularization. In the current review, we focus on clinical applications of IVUS in interventional cardiology. J Am Coll Cardiol Intv. 2011;4(11):1155-1167. doi:10.1016/j.jcin.2011.07.013. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 noviembre 2012

JACC CARDIOVASCULAR INTERVENTIONS. A New Score for Risk Stratification of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Tullio Palmerini, MD; Philippe Genereux, MD; Adriano Caixeta, MD; Ecaterina Cristea, MD; Alexandra Lansky, MD; Roxana Mehran, MD; Diego Della Riva, MD; Martin Fahy, MSc; Ke Xu, PhD; Gregg W. Stone, MD

The ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy–Percutaneous Coronary Intervention) Risk Score. J Am Coll Cardiol Intv. 2012;5(11):1108-1116. doi:10.1016/j.jcin.2012.07.011. Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 octubre 2011

CIRCULATION. Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention

Robert W. Yeh, MD, MSc; Sharon-Lise T. Normand, PhD; Robert E. Wolf, MS; Philip G. Jones, MS; Kalon K.L. Ho, MD, MSc; David J. Cohen, MD, MSc; Donald E. Cutlip, MD; Laura Mauri, MD, MSc; Aaron D. Kugelmass, MD; Amit P. Amin, MD; John A. Spertus, MD, MPH

Background—Drug-eluting stents (DES) for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. To assist physicians in targeting DES use in patients at the highest risk for target vessel revascularization (TVR), we developed and validated a model to predict TVR. Circulation. 2011; 124: 1557-1564 Published online before print September 6, 2011, doi: 10.1161/​CIRCULATIONAHA.111.045229. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

01 octubre 2012

EUROPEAN HEART JOURNAL. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit

Sandeep R. Gangireddy, Jonathan L. Halperin, Valentin Fuster and Vivek Y. Reddy

Aims: The PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial found left atrial appendage (LAA) closure an alternative to anticoagulation in selected patients with non-valvular atrial fibrillation (AF). We aim to estimate the net clinical benefit (NCB) of percutaneous LAA closure. Eur Heart J (2012) 33 (21): 2700-2708. doi: 10.1093/eurheartj/ehs292 First published online: September 24, 2012. Published on behalf of the European Society of Cardiology. All rights reserved. Copyright © The Author 2012.

01 octubre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Clinical Utility of Regadenoson for Assessing Fractional Flow Reserve

Pradeep K. Nair, MD; Oscar C. Marroquin, MD; Suresh R. Mulukutla, MD; Sameer Khandhar, MD; Vijay Gulati, MD; John T. Schindler, MD; Joon S. Lee, MD

Objectives The aim of this study was to evaluate the efficacy of regadenoson, in comparison with adenosine, for assessing fractional flow reserve (FFR) of intermediate coronary artery stenoses (CAS). J Am Coll Cardiol Intv. 2011;4(10):1085-1092. doi:10.1016/j.jcin.2011.07.011. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 octubre 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Comparison of Resolute Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With De Novo Long Coronary Artery Lesions A Randomized LONG-DES IV Trial

Jung-Min Ahn, MD, Duk-Woo Park, MD, Young-Hak Kim, MD, HaeGeun Song, MD, Young-Rak Cho, MD, Won-Jang Kim, MD, Jong-Young Lee, MD, Soo-Jin Kang, MD, Seung-Whan Lee, MD, Cheol Whan Lee, MD, Seong-Wook Park, MD, Sung-Cheol Yun, PhD, Seungbong Han, PhD, Sung Yun Lee, MD, Bong-Ki Lee, MD, Jang-Hyun Cho, MD, Tae-Hyun Yang, MD, Nae-Hee Lee, MD, Joo-Young Yang, MD, Jong-Seon Park, MD, Won-Yong Shin, MD, Moo Hyun Kim, MD, Jang Ho Bae, MD, Myeong-Kon Kim, MD, Junghan Yoon, MD and Seung-Jung Park, MD

Background—Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo stent-based coronary interventions. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and sirolimus-eluting stents (SES) for patients with de novo long coronary lesions. Circulation: Cardiovascular Interventions. 2012; 5: 633-640 Published online before print October 9, 2012, doi: 10.1161/​CIRCINTERVENTIONS.111.965673. Copyright © 2012 American Heart Association, Inc.

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Intravascular Ultrasound-Derived Predictors for Fractional Flow Reserve in Intermediate Left Main Disease

Soo-Jin Kang, MD, PhD; Jong-Young Lee, MD; Jung-Min Ahn, MD; Hae Geun Song, MD; Won-Jang Kim, MD; Duk-Woo Park, MD, PhD; Sung-Cheol Yun, PhD; Seung-Whan Lee, MD, PhD; Young-Hak Kim, MD, PhD; Gary S. Mintz, MD; Cheol Whan Lee, MD, PhD; Seong-Wook Park, MD, PhD; Seung-Jung Park, MD, PhD

Objectives: The aim of this study was to determine the best intravascular ultrasound (IVUS) criteria for predicting physiological significance of left main (LM) stenosis with fractional flow reserve (FFR) as the standard. J Am Coll Cardiol Intv. 2011;4(11):1168-1174. doi:10.1016/j.jcin.2011.08.009 Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 octubre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Long Coronary Artery Lesions

Duk-Woo Park, MD; Young-Hak Kim, MD; Hae-Geun Song, MD; Jung-Min Ahn, MD; Won-Jang Kim, MD; Jong-Young Lee, MD; Soo-Jin Kang, MD; Seung-Whan Lee, MD; Cheol Whan Lee, MD; Seong-Wook Park, MD; Sung-Cheol Yun, PhD; Ki-Bae Seung, MD; Tae-Hyun Yang, MD; Sang-Gon Lee, MD; Jae-Hwan Lee, MD; In-Whan Seong, MD; Sang-Sig Cheong, MD; Bong-Ki Lee, MD; Nae-Hee Lee, MD; Se-Whan Lee, MD; Seung-Wook Lee, MD; Keun Lee, MD; Hyun-Sook Kim, MD; Doo-Soo Jeon, MD; Min-Kyu Kim, MD; Deuk-Young Nah, MD; Seung-Jea Tahk, MD; Seung-Jung Park, MD

A Randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. J Am Coll Cardiol Intv. 2011;4(10):1096-1103. doi:10.1016/j.jcin.2011.05.024. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 octubre 2011

CIRCULATION. Arterial Pulse Wave Dynamics After Percutaneous Aortic Valve Replacement. Fall in Coronary Diastolic Suction With Increasing Heart Rate as a Basis for Angina Symptoms in Aortic Stenosis

Justin E. Davies, MRCP; Sayan Sen, MRCP; Chris Broyd, MRCP; Nearchos Hadjiloizou, MRCP; John Baksi, MRCP; Darrel P. Francis, FRCP; Rodney A. Foale, FRCP; Kim H. Parker, PhD; Alun D. Hughes, PhD; Andrew Chukwuemeka, FRCS; Roberto Casula, FRCS; Iqbal S. Malik, FRCP; Ghada W. Mikhail, FRCP; Jamil Mayet, FRCP

Background—Aortic stenosis causes angina despite unobstructed arteries. Measurement of conventional coronary hemodynamic parameters in patients undergoing valvular surgery has failed to explain these symptoms. With the advent of percutaneous aortic valve replacement (PAVR) and developments in coronary pulse wave analysis, it is now possible to instantaneously abolish the valvular stenosis and to measure the resulting changes in waves that direct coronary flow. Circulation. 2011; 124: 1565-1572 Published online before print September 12, 2011, doi: 10.1161/​CIRCULATIONAHA.110.011916. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

01 octubre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes

David Planer, MD, MSc; Pieter C. Smits, MD; Dean J. Kereiakes, MD; Elvin Kedhi, MD; Martin Fahy, MSc; Ke Xu, PhD; Patrick W. Serruys, MD, PhD; Gregg W. Stone, MD

Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. J Am Coll Cardiol Intv. 2011;4(10):1104-1115. doi:10.1016/j.jcin.2011.06.018. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 octubre 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study

John A. Ormiston, MBChB, Patrick W. Serruys, MD, PhD, Yoshinobu Onuma, MD, Robert-Jan van Geuns, MD, PhD, Bernard de Bruyne, MD, PhD, Dariusz Dudek, MD, Leif Thuesen, MD, Pieter C. Smits, MD, PhD, Bernard Chevalier, MD, Dougal McClean, MBChB, Jacques Koolen, MD, PhD, Stephan Windecker, MD, Robert Whitbourn, MBBS, Ian Meredith, MBBS, PhD, Cecile Dorange, MSc, Susan Veldhof, RN, Karine Miquel Hebert, PhD, Richard Rapoza, PhD and Hector M. Garcia-Garcia, MD, PhD

Background—Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Circulation: Cardiovascular Interventions. 2012; 5: 620-632 Published online before print October 9, 2012, doi: 10.1161/​CIRCINTERVENTIONS.112.971549. Copyright © 2012 American Heart Association, Inc.

01 octubre 2011

CIRCULATION. Idiopathic Pulmonary Artery Aneurysm

Masaru Seguchi, MD; Hiroshi Wada, MD; Kenichi Sakakura, MD; Norifumi Kubo, MD; Nahoko Ikeda, MD; Yoshitaka Sugawara, MD; Atsushi Yamaguchi, MD; Junya Ako, MD; Shin-ichi Momomura, MD

A 45-year-old man was referred to our hospital after a prolonged history of exertional dyspnea. Circulation. 2011; 124: e369-e370 doi: 10.1161/​CIRCULATIONAHA.111.029033. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

01 octubre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Three-Dimensional Reconstruction of the Post-Dilated ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold in a True Bifurcation Lesion for Flow Restoration FREE

Bill D. Gogas, MD; Robert J. van Geuns, MD, PhD; Vasim Farooq, MBChB; Evelyn Regar, MD, PhD; Jung Ho Heo, MD; Jurgen Ligthart, BSc; Patrick W. Serruys, MD, PhD

J Am Coll Cardiol Intv. 2011;4(10):1149-1150. doi:10.1016/j.jcin.2011.05.026. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 octubre 2011

CIRCULATION: CARDIOVASULAR INTERVENTIOS. Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. Results From the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry

Jason B. Lindsey, MD, Kevin F. Kennedy, MS, Joshua M. Stolker, MD, Ian C. Gilchrist, MD, Debabrata Mukherjee, MD, Steven P. Marso, MD, Michael J. Pencina, PhD, Neal S. Kleiman, MD and David J. Cohen, MD, MSc

Background—Creatine kinase-MB (CK-MB) elevation after percutaneous coronary intervention (PCI) has been associated with increased risk for mortality. Although most studies have defined periprocedural myocardial infarction (pMI) as an elevation in CK-MB >3× upper limit of normal (ULN), use of different CK-MB assays and variation in site-specific definitions of the ULN may limit the value of such relative thresholds. Circulation: Cardiovascular Interventions. 2011; 4: 474-480 Published online before print October 4, 2011, doi: 10.1161/​CIRCINTERVENTIONS.111.962233. Copyright © 2012 American Heart Association, Inc.